FluoroPharma Medical (FluoroPharma Medical) Interest Expense : $-1.26 Mil (TTM As of Dec. 2016)

View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. FluoroPharma Medical's interest expense for the three months ended in Dec. 2016 was $ -0.20 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2016 was $-1.26 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. FluoroPharma Medical's Operating Income for the three months ended in Dec. 2016 was $ -0.52 Mil. FluoroPharma Medical's Interest Expense for the three months ended in Dec. 2016 was $ -0.20 Mil. FluoroPharma Medical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

FluoroPharma Medical Interest Expense Historical Data

The historical data trend for FluoroPharma Medical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoroPharma Medical Interest Expense Chart

FluoroPharma Medical Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Interest Expense

Get a 7-Day Free Trial

-0.05

-0.10

-0.87

-1.26

FluoroPharma Medical Quarterly Data
	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16
Interest Expense	Get a 7-Day Free Trial															-0.48	-0.40	-0.46	-0.21	-0.20

FluoroPharma Medical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.26 Mil.

FluoroPharma Medical (OTCPK:FPMI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

FluoroPharma Medical's Interest Expense for the three months ended in Dec. 2016 was $-0.20 Mil. Its Operating Income for the three months ended in Dec. 2016 was $-0.52 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2016 was $0.00 Mil.

FluoroPharma Medical's Interest Coverage for the quarter that ended in Dec. 2016 is calculated as

FluoroPharma Medical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

FluoroPharma Medical (FluoroPharma Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042

Website

http://www.fluoropharma.com

FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.

Executives

Johan M. Spoor

director, officer: CEO, PRESIDENT, CHAIRMAN

500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus

FPMI Restructures CardioPET License With Massachusetts General Hospital

By Marketwired Marketwired • 09-27-2018